• 1
    Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev 2001; 23: 313.
  • 2
    Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1: 3445.
  • 3
    Dagher R, Li N, Abraham S, Rahman A, Sridhara R, Pazdur R. Approval summary: docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer. Clin Cancer Res 2004; 10: 814751.
  • 4
    Kasper S, Cookson MS. Mechanisms leading to the development of hormone-resistant prostate cancer. Urol Clin North Am 2006; 33: 201210.
  • 5
    Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69: 230513.
  • 6
    Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009; 69: 15160.
  • 7
    Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A, Jarrard DF. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 2000; 60: 362330.
  • 8
    Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa Y, Mizokami A, Ito H, Yatani R, Shiraishi T. Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 2000; 80: 178996.
  • 9
    Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J Endocrinol Invest 2005; 28: 1415.
  • 10
    Sharifi N, Kawasaki BT, Hurt EM, Farrar WL. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy. Cancer Biol Ther 2006; 5: 901906.
  • 11
    Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005; 11: 46537.
  • 12
    Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008; 68: 67629.
  • 13
    Gupta S, Afaq F, Mukhtar H. Selective growth-inhibitory, cell-cycle deregulatory and apoptotic response of apigenin in normal versus human prostate carcinoma cells. Biochem Biophys Res Commun 2001; 287: 91420.
  • 14
    Bosland MC, Kato I, Melamed J, Taneja S, Lepor H, Torre P, Walden P, Zeleniuch-Jacquotte A, Lumey LH. Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: application to efficacy assessment of soy protein. Urology 2001; 57( 4 Suppl 1): 2024.
  • 15
    Moyad MA. The use of complementary/preventive medicine to prevent prostate cancer recurrence/progression following definitive therapy. Part II--rapid review of dietary supplements. Curr Opin Urol 2003; 13: 14751.
  • 16
    Knowles LM, Zigrossi DA, Tauber RA, Hightower C, Milner JA. Flavonoids suppress androgen-independent human prostate tumor proliferation. Nutr Cancer 2000; 38: 11622.
  • 17
    Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE,Jr, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112: 16509.
  • 18
    Singh YN. Kava: an overview. J Ethnopharmacol 1992; 37: 1345.
  • 19
    Steiner GG. The correlation between cancer incidence and kava consumption. Hawaii Med J 2000; 59: 4202.
  • 20
    Zi X, Simoneau AR. Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice. Cancer Res 2005; 65: 347986.
  • 21
    Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 2755.
  • 22
    Tang Y, Simoneau AR, Xie J, Shahandeh B, Zi X. Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53. Cancer Prev Res 2008; 1: 43951.
  • 23
    Dharmaratne HR, Nanayakkara NP, Khan IA. Kavalactones from Piper methysticum, and their 13C NMR spectroscopic analyses. Phytochemistry 2002; 59: 42933.
  • 24
    Finnberg N, El-Deiry WS. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle 2008; 7: 15258.
  • 25
    Kim H, Rafiuddin-Shah M, Tu HC, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH. Hierarchical regulation of mitochondrial-dependent apoptosis by BCL-2 subfamilies. Nat Cell Biol 2006; 8: 134858.
  • 26
    Ho PK, Hawkins CJ. Mammalian initiator apoptotic caspases. FEBS J 2005; 272: 543653.
  • 27
    Peehl DM. Primary cell cultures as models of prostate cancer development. Endocr Relat Cancer 2005; 12: 1947.
  • 28
    Zhang Y, Nan B, Yu J, Snabboon T, Andriani F, Marcelli M. From castration-induced apoptosis of prostatic epithelium to the use of apoptotic genes in the treatment of prostate cancer. Ann N Y Acad Sci 2002; 963: 191203.
  • 29
    Catz SD, Johnson JL. BCL-2 in prostate cancer: a mini-review. Apoptosis 2003; 8: 2937.
  • 30
    Gao S, Lee P, Wang H, Gerald W, Adler M, Zhang L, Wang YF, Wang Z. The androgen receptor directly targets the cellular Fas/FasL-associated death domain protein-like inhibitory protein gene to promote the androgen-independent growth of prostate cancer cells. Mol Endocrinol 2005; 19: 1792802.
  • 31
    Gleave ME, Zellweger T, Chi K, Miyake H, Kiyama S, July L, Leung S. Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer. Invest New Drugs 2002; 20: 14558.
  • 32
    Wang W, Kim SH, El-Deiry WS. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad Sci USA 2006; 103: 110038.
  • 33
    Liu Z, Li B, Li X, Simoneau A, Zi X. The Kava chalcone Flavokawain A potentiates the inhibitory effect of Nutilin-3a on cancer cell growth via enhancement of p53 activity. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research, April 18–22, 2009, Denver, CO; Philadelphia (PA): AACR, 2009. Abstract no. 4728.
  • 34
    Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, Tu HC, Kim H, Cheng EH, Tjandra N, Walensky LD. BAX activation is initiated at a novel interaction site. Nature 2008; 455: 107681.
  • 35
    Erlacher M, Labi V, Manzl C, Böck G, Tzankov A, Häcker G, Michalak E, Strasser A, Villunger A. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med 2006; 203: 293951.
  • 36
    Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 61649.
  • 37
    Zantl N, Weirich G, Zall H, Seiffert BM, Fischer SF, Kirschnek S, Hartmann C, Fritsch RM, Gillissen B, Daniel PT, Häcker G. Frequent loss of expression of the pro-apoptotic protein Bim in renal cell carcinoma: evidence for contribution to apoptosis resistance. Oncogene 2007; 2: 703848.
  • 38
    Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, Morishima Y, Nakamura S, Seto M. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 134858.
  • 39
    Ley R, Ewings KE, Hadfield K, Howes E, Balmanno K, Cook SJ. Extracellular signal-regulated kinases 1/2 are serum-stimulated “Bim(EL) kinases” that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem 2004; 279: 883747.
  • 40
    Guo Y, Schoell MC, Freeman RS. The von Hippel-Lindau protein sensitizes renal carcinoma cells to apoptotic stimuli through stabilization of BIM(EL). Oncogene 2009; 28: 186474.
  • 41
    Qi XJ, Wildey GM, Howe PH. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 2006; 281: 81323.
  • 42
    Sunters A, Fernández de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffer PJ, Medema RH, Coombes RC, Lam EW. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 2003; 278: 49795805.
  • 43
    Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118: 305164.